IRLAB Therapeutics AB Class A (IRLAB.A) AI Stock Analysis

• Market Cap: kr208.77M
• Dividend Yield: N/A
• Average Volume (3M): 76.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.06
• Revenue Growth: 1643.36%
• EPS Growth: 50.36%
• Country: SE
• Employees: 31
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.66
• Shares Outstanding: 51,788,630
• 10 Day Avg. Volume: 179,137
• 30 Day Avg. Volume: 76,737
• PEG Ratio: 0.05
• Price to Book (P/B): 6.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: kr3.50 ▼(-9.56%Downside)

IRLAB Therapeutics scores poorly across financial performance, technical analysis, and valuation. The company's financial struggles and weak market indicators significantly impact its overall stock score, suggesting high risk and unattractive investment potential.

IRLAB Therapeutics AB Class A Business Overview & Revenue Model

Company Description

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.

How the Company Makes Money

IRLAB Therapeutics AB generates revenue through the development and commercialization of pharmaceutical products targeting neurological conditions. The company primarily earns money by licensing its drug candidates to larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Additionally, IRLAB may engage in partnerships and collaborations to advance its drug development programs, providing further financial resources and expertise. The company's innovative ISP platform also contributes to its revenue by enabling the identification of promising drug candidates, thereby attracting investment and partnership opportunities.

IRLAB Therapeutics AB Class A Financial Statement Overview

Summary

IRLAB Therapeutics is struggling with profitability and cash flow management. Despite revenue growth, operational inefficiencies and high leverage pose significant financial challenges. Improvements in margin and cash flow generation are necessary for financial stability.

Income Statement

IRLAB Therapeutics has shown a volatile revenue trend with a significant increase in 2024, but remains unprofitable with negative net margins. The gross profit margin is positive for 2024, indicating improvements, but EBIT and EBITDA margins remain negative, highlighting operational inefficiencies.

Balance Sheet

The company has a high debt-to-equity ratio due to rising debt levels and declining equity, which could pose financial risks. The equity ratio is relatively low, reflecting limited equity financing. ROE is negative due to consistent net losses, indicating poor shareholder returns.

Cash Flow

IRLAB Therapeutics faces challenges in cash flow management with consistent negative free cash flow, indicating cash burn. The operating cash flow to net income ratio remains concerningly low, suggesting inefficiencies in converting revenue into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	98.99M	94.63M	5.68M	61.14M	207.78M	300.00K
Gross Profit	-50.70M	-92.42M	-122.73M	-111.23M	168.69M	-1.70M
EBITDA	-59.58M	-68.07M	-173.32M	-109.13M	55.37M	-89.46M
Net Income	-78.08M	-83.13M	-177.84M	-114.20M	51.78M	-91.85M
Balance Sheet
Total Assets	159.72M	136.21M	177.12M	323.56M	472.45M	370.07M
Cash, Cash Equivalents and Short-Term Investments	88.61M	66.92M	111.31M	252.78M	401.90M	277.01M
Total Debt	66.46M	60.42M	27.57M	3.98M	6.60M	2.93M
Total Liabilities	155.09M	103.58M	61.36M	32.72M	72.97M	22.19M
Stockholders Equity	4.63M	32.63M	115.76M	290.83M	399.48M	347.88M
Cash Flow
Free Cash Flow	-21.25M	-65.79M	-165.14M	-145.99M	127.93M	-89.61M
Operating Cash Flow	-21.05M	-65.59M	-164.85M	-142.61M	128.64M	-89.21M
Investing Cash Flow	-199.00K	-199.00K	-293.00K	-3.38M	-708.00K	-394.00K
Financing Cash Flow	36.71M	21.40M	23.68M	-3.13M	-3.04M	256.09M

IRLAB Therapeutics AB Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRLAB.A, the sentiment is Negative. The current price of 3.87 is below the 20-day moving average (MA) of 6.43, below the 50-day MA of 6.84, and below the 200-day MA of 10.54, indicating a bearish trend. The MACD of -0.76 indicates Positive momentum. The RSI at 18.91 is Positive, neither overbought nor oversold. The STOCH value of 7.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IRLAB.A.

IRLAB Therapeutics AB Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMMU	54 Neutral	kr393.24M	―	-18.79%	―	―	21.85%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	16.99%	1.69%
XBRANE	47 Neutral	€386.11M	―	-47.73%	―	45.52%	93.35%
ONCO	40 Underperform	kr312.67M	―		―	1.72%	32.54%
IRLAB.A	37 Underperform	kr208.77M	―	-194.31%	―	1643.36%	50.36%
GUARD	32 Underperform	€334.78M	―	-205.65%	―	―	24.25%
CANTA	31 Underperform	kr311.26M	―	-167.55%	―	―	46.67%

IRLAB Therapeutics AB Class A Corporate Events

IRLAB Therapeutics Secures Funding for Parkinson’s Drug Development

IRLAB Therapeutics AB has announced an 85% secured rights issue to raise approximately SEK 136 million, with an extended debt financing of SEK 30 million. The funds will support business development and the advancement of drug candidates, strengthening the company’s financial position and enhancing its appeal in partnership discussions.

IRLAB Therapeutics AB 2025 Annual General Meeting Resolutions

IRLAB Therapeutics AB held its Annual General Meeting on June 11, 2025, where several key resolutions were adopted. The meeting approved the financial statements for 2024, decided to carry forward the company’s results without distributing dividends, and re-elected board members and auditors. Additionally, the board’s remuneration was set with a conditional reduction until certain financial targets are met. The meeting also authorized the board to issue new shares or warrants with preferential rights for shareholders.

IRLAB Therapeutics to Present at Aktiedagarna Event in Stockholm

IRLAB Therapeutics AB announced its participation in the Aktiedagarna event in Stockholm, where CEO Kristina Torfgård will present the company’s developments on June 10. This engagement highlights IRLAB’s active role in the industry, potentially enhancing its visibility and stakeholder engagement as it progresses its Parkinson’s disease treatment pipeline.

IRLAB Therapeutics Reports Positive Phase I Results for IRL757

IRLAB Therapeutics AB has announced positive results from the second part of its Phase I study for IRL757, a drug candidate aimed at treating apathy in neurodegenerative diseases. The study, funded by The Michael J. Fox Foundation, showed that IRL757 is well absorbed and tolerated, supporting further clinical development. The company has initiated a Phase Ib study in collaboration with The McQuade Center for Strategic Research and Development, with plans to enroll the first patients in late 2025. This development positions IRLAB as a potential leader in addressing apathy, a significant unmet medical need in Parkinson’s and Alzheimer’s diseases.

IRLAB Therapeutics to Present at BioStock Global Forum 2025

IRLAB Therapeutics AB announced that CEO Kristina Torfgård will present at the BioStock Global Forum 2025, an event aimed at connecting with potential partners and investors in the pharmaceutical industry. This presentation offers IRLAB a strategic opportunity to expand its network and establish new partnerships, potentially impacting its market positioning and stakeholder engagement.

IRLAB Secures Extended US Patent for Mesdopetam

IRLAB Therapeutics AB has been granted a new patent in the US for the salt form of its drug candidate mesdopetam, which is aimed at treating levodopa-induced dyskinesias in Parkinson’s disease patients. This patent extends the company’s market exclusivity into the 2040s, enhancing the value of mesdopetam and reinforcing IRLAB’s position in the Parkinson’s treatment market.

IRLAB Therapeutics Reports Strong Q1 2025 Progress with Regulatory and Clinical Advances

IRLAB Therapeutics AB reported significant progress in the first quarter of 2025, with positive regulatory feedback from the EMA aligning with the FDA on Phase III for Mesdopetam and promising Phase I results for IRL757. The company also announced a fully funded IRL757 study in Parkinson’s disease and a Phase IIB study with Pirepemat showing a meaningful reduction in fall frequency, strengthening its market position and operational outlook.